SK285584B6 - Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia - Google Patents

Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia Download PDF

Info

Publication number
SK285584B6
SK285584B6 SK898-2000A SK8982000A SK285584B6 SK 285584 B6 SK285584 B6 SK 285584B6 SK 8982000 A SK8982000 A SK 8982000A SK 285584 B6 SK285584 B6 SK 285584B6
Authority
SK
Slovakia
Prior art keywords
cancer
compound
mpk
paclitaxel
proliferative disease
Prior art date
Application number
SK898-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK8982000A3 (en
Inventor
Walter R. Bishop
Joseph J. Catino
Ronald J. Doll
Ashit Ganguly
Viyyoor Girijavallabhan
Paul Kirschmeier
Ming Liu
Loretta L. Nielsen
David L. Cutler
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285584(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of SK8982000A3 publication Critical patent/SK8982000A3/sk
Publication of SK285584B6 publication Critical patent/SK285584B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK898-2000A 1997-12-22 1998-12-21 Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia SK285584B6 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (fr) 1997-12-22 1998-12-21 Combinaison de composes benzocycloheptapyridines et medicaments antineoplasiques pour le traitement de maladies proliferantes

Publications (2)

Publication Number Publication Date
SK8982000A3 SK8982000A3 (en) 2001-04-09
SK285584B6 true SK285584B6 (sk) 2007-04-05

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
SK898-2000A SK285584B6 (sk) 1997-12-22 1998-12-21 Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia

Country Status (25)

Country Link
EP (1) EP1041985B1 (fr)
JP (1) JP4502503B2 (fr)
KR (1) KR100700907B1 (fr)
CN (1) CN1129431C (fr)
AR (1) AR017440A1 (fr)
AT (1) ATE317697T1 (fr)
AU (1) AU756762B2 (fr)
BR (1) BR9814419A (fr)
CA (1) CA2315693C (fr)
CL (1) CL2007001889A1 (fr)
CO (1) CO5080764A1 (fr)
CZ (1) CZ298511B6 (fr)
DE (1) DE69833509T2 (fr)
DK (1) DK1041985T3 (fr)
ES (1) ES2255196T3 (fr)
HU (1) HUP0102473A3 (fr)
IL (1) IL136462A0 (fr)
MY (1) MY137303A (fr)
NO (1) NO326832B1 (fr)
NZ (1) NZ504928A (fr)
PE (1) PE20000042A1 (fr)
PT (1) PT1041985E (fr)
SK (1) SK285584B6 (fr)
TW (1) TW581763B (fr)
WO (1) WO1999032114A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
JP2003513940A (ja) * 1999-11-09 2003-04-15 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ヘテロ三量体ｇタンパク質情報の伝達抑制剤と他の抗癌剤とからなる、癌の処置において治療の目的に使用する製品
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1261348A2 (fr) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
CA2397690A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
WO2001064198A2 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux
JP2003525246A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397253A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
EP1263437A2 (fr) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de vinca-alcaloides
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (fr) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de la farnesyle proteine transferase avec agents anti-oestrogene
BR0214564A (pt) * 2001-11-30 2004-11-09 Schering Corp Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
CN1849122A (zh) * 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
EP0856315B1 (fr) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Inhibiteurs de la proteine farnesyltransferase en combinaison avec des inhibiteurs de hmgcoa-reductase pour le traitement de sida
WO1997023478A1 (fr) * 1995-12-22 1997-07-03 Schering Corporation Amides tricycliques destines a l'inhibition de la fonction de la proteine-g et au traitement des maladies proliferatives
JP3737518B2 (ja) * 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
EP0952842A2 (fr) * 1996-04-18 1999-11-03 Merck & Co., Inc. Methode de traitement de cancer
EP0934270A1 (fr) * 1996-05-30 1999-08-11 Merck & Co., Inc. Procede de traitement du cancer
DE69734785T2 (de) * 1997-01-29 2006-08-03 Picker Medical Systems, Ltd. Vorherbestimmung zur verfolgung der optimalen kontrastmittelkonzentration
ATE361668T1 (de) * 1997-02-18 2007-06-15 Canji Inc Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Also Published As

Publication number Publication date
MY137303A (en) 2009-01-30
NO326832B1 (no) 2009-02-23
NO20003229L (no) 2000-08-22
TW581763B (en) 2004-04-01
AU1907299A (en) 1999-07-12
EP1041985A1 (fr) 2000-10-11
CA2315693C (fr) 2010-11-30
JP4502503B2 (ja) 2010-07-14
DE69833509T2 (de) 2006-10-26
DK1041985T3 (da) 2006-06-19
ATE317697T1 (de) 2006-03-15
CZ298511B6 (cs) 2007-10-24
IL136462A0 (en) 2001-06-14
CN1129431C (zh) 2003-12-03
DE69833509D1 (de) 2006-04-20
SK8982000A3 (en) 2001-04-09
PT1041985E (pt) 2006-07-31
BR9814419A (pt) 2000-10-10
CA2315693A1 (fr) 1999-07-01
AU756762B2 (en) 2003-01-23
CL2007001889A1 (es) 2008-01-11
KR20010033452A (ko) 2001-04-25
CO5080764A1 (es) 2001-09-25
JP2001526224A (ja) 2001-12-18
PE20000042A1 (es) 2000-02-17
KR100700907B1 (ko) 2007-03-29
NO20003229D0 (no) 2000-06-21
NZ504928A (en) 2004-12-24
EP1041985B1 (fr) 2006-02-15
CN1284875A (zh) 2001-02-21
HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 (en) 2003-07-28
WO1999032114A1 (fr) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
ES2255196T3 (es) 2006-06-16
AR017440A1 (es) 2001-09-05

Similar Documents

Publication Publication Date Title
US6333333B1 (en) Methods for treating proliferative diseases
US6316462B1 (en) Methods of inducing cancer cell death and tumor regression
SK285584B6 (sk) Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia
RU2264217C2 (ru) Синергические способы и композиции для лечения рака
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
JP2013503171A (ja) がんの処置および予防におけるメトホルミンの使用
US20070117784A1 (en) Treatment of hyperproliferative diseases with anthraquinones
US6777415B2 (en) Methods of inducing cancer cell death and tumor regression
BG107281A (bg) Комбиниран химиотерапевтичен състав
BR112021007283A2 (pt) método de tratamento de um câncer ou câncer refratário
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
BG108605A (bg) Използване на състави при лечението на рак
AU2007334381A1 (en) Compositions and methods for the treatment of cancer
US20160368980A1 (en) Inhibition of granulocyte colony stimulating factor in the treatment of cancer
EP3976039A1 (fr) Composés bisaminoquinolines et bisaminoacridines et leurs méthodes d'utilisation
CN107404876B (zh) 抗癌治疗剂
RU2284818C2 (ru) Комбинированная химиотерапия
WO2023107894A1 (fr) Polythérapie comprenant un inhibiteur de pkc et un inhibiteur de c-met
TWI528960B (zh) 用於治療增生性疾病的醫藥組合物
MXPA00006257A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20101221